Bepranemab (UCB Biopharma SRL) is a humanized IgG4 monoclonal antibody selected for its efficacy in blocking human tau seeds in vitro and was generated by immunizing Sprague–Dawley rats with fibrils of recombinant tau (Figure 4d).[26, 100] Bepranemab was originally tested in phase I clinical trials for safety, tolerability, and efficacy against progressive supranuclear palsy.[101, 102] It is now being tested in a phase II clinical trial for AD, which is expected to be completed in 2025.[103]. Here, MAPT is linked to progressive supranuclear palsy.